Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tannic acid in antithrombotic drugs

An antithrombotic drug, tannic acid technology, applied in the field of prevention and treatment of thrombosis, tannic acid, to achieve broad application prospects, stable physical and chemical properties, and mature production technology

Inactive Publication Date: 2017-05-31
SUZHOU UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of tannic acid in platelet and thrombotic diseases has not been reported at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tannic acid in antithrombotic drugs
  • Application of tannic acid in antithrombotic drugs
  • Application of tannic acid in antithrombotic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] The inhibitory effect of tannic acid on isolated platelet aggregation is as follows:

[0027] (1) Preparation of washed platelets

[0028]20% citric acid-glucose solution (ACD, pH4.4) (recipe: trisodium citrate 65mM, citric acid 70mM, glucose 100mM) anticoagulant venous blood from healthy volunteers, centrifuged at 900r / min for 20min to prepare platelet-rich Plasma (PRP), PRP passed through the agarose gel sepharose2BTM column that had been washed and equilibrated with Tyrode's buffer, and the washed platelets for experiments were collected from the lower end of the column. Platelets were counted, and the platelet concentration was adjusted to 250×10 with Tyrode's buffer 6 ml -1 .

[0029] (2) Determination of platelet aggregation stimulated by CRP

[0030] The platelet aggregation instrument (CHRONO-LOG) was turned on and warmed up 30 minutes before the experiment. Take 4 cuvettes (CHRONO-LOG, model P / N312) specially used for platelet aggregation analyzer (CHRONO-...

Embodiment 2

[0035] Inhibitory effect of tannic acid on activation of isolated platelets, as follows:

[0036] (1) Preparation of washed platelets

[0037] 20% ACD (pH4.4) (recipe: trisodium citrate 65mM, citric acid 70mM, glucose 100mM) anticoagulant venous blood from healthy volunteers, centrifuged at 900r / min for 20min to prepare platelet-rich plasma (PRP), PRP Wash and equilibrate the sepharose2BTM gel column with Tyrode's buffer, pick up the platelets used for the experiment from the lower end of the column, count the platelets, adjust the platelet concentration to 250×10 with Tyrode's buffer 6 ml -1 .

[0038] (2) P-selectin expression test

[0039] 100 μL of the washed platelets prepared above were added to the 4 sample loading tubes respectively, and 1 μL of tannic acid solutions with concentrations of 10, 30 and 50 μM (normal saline as solvent) and 1 μL of normal saline (blank control group) were added to the washed platelets. Under the condition of adding fluorescent PE-P-sel...

Embodiment 3

[0045] Effects of tannic acid on laser-induced arterial thrombus in the cremaster muscle of mice, as follows:

[0046] Inject tannic acid (7.5 mg / kg) and an equal volume of normal saline (blank control group) into the wild-type mice intraperitoneally, anesthetize half an hour later, inject DIOC6 dye intravenously, and damage the free cremaster muscle artery with laser pulses. Thrombosis was observed and recorded under a microscope. see results Figure 4 , A shows the curve of thrombus size changing with time, D is the microscopic magnified view of the largest thrombus formed, the results all show that compared with the blank control group, tannic acid has the effect on the laser when the dose is 7.5mg / kg (intraperitoneal injection). Induced arterial thrombus of cremaster muscle in mice has obvious inhibitory effect. Figure 4 In B and C, the total volume and peak volume of the thrombus in the tannic acid administration group were smaller than those in the blank control group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of tannic acid in preparation of antithrombotic drugs and particularly drugs for inhibiting platelet activation / aggregation. According to in-vitro and animal studies, the natural compound tannic acid can obviously inhibit the platelet phospholipid splicing, activation and aggregation at low concentration and shows remarkable anti-platelet and antithrombotic effects without increasing the risk of bleeding; the tannic acid can be extracted from plants or synthesized industrially, and the production cost is low; and moreover, the tannic acid, developed as a novel anti-platelet drug, has broad application prospects and huge market potential and social values.

Description

technical field [0001] The present invention is designed in the field of medicine, and particularly relates to the use of one or several combinations of tannic acid, the hydrolyzed product or derivatives as the prevention and treatment of thrombus. Background technique [0002] Thrombosis is the abnormal coagulation of blood components in local blood vessels of the human body, which can occur in arteries or veins. Arterial thrombosis is the main cause of more than 90% of myocardial infarction and 80% of stroke. Arterial thromboembolic cardiovascular disease has always been the leading cause of death in developed countries; deep vein thrombosis and pulmonary embolism are collectively referred to as venous thromboembolism, which is It is the third leading cause of death from cardiovascular-related diseases after myocardial infarction and stroke. The pathophysiological basis of arterial thrombosis and venous thrombosis is different, fully understanding and mastering this diffe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7024A61P7/02
CPCA61K31/7024
Inventor 朱力尤涛唐朝君
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com